In mouse experiments reported in the November 24 issue of Science, the Hopkins researchers demonstrated that genetically-modified bacteria called Clostridium novyi-NT (C.novy-NT) have a special taste for oxygen-starved environments much like those found in the core of cancer cell clusters. The modified bacteria themselves are relatively harmless, but their unmodified counterparts produce poisons that have killed some humans and cattle when introduced into the bloodstream.
“It is not difficult to kill cancer cells. The challenge is killing them while sparing normal cells,” says Bert Vogelstein, M.D., professor and co-director of the Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center.
The bacteria’s cancer-killing effects were first discovered five years ago by the Hopkins team who noticed the germ’s ability to grow and spread in the oxygen-poor core of mouse tumors and the blackened scars signaling that most of the cancer cells had been destroyed. Normal surrounding cells were largely unaffected. But the bacteria failed to kill cancer cells at the still oxygen-rich edge of the tumors.
In response, the Hopkins team added specially-packaged chemotherapy to the bacterial attack speculating that certain properties of the bacteria would improve the drug’s effectiveness, according to Shibin Zhou, M.D., Ph.D., assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center.
The combo approach temporarily wiped out both large and small tumors in almost 100 mice and permanently cured more than two-thirds of them.
The likely explanation for the greater cancer cell kill by the combination treatment is that the bacteria expose the tumors to six times the amount of chemotherapy than is usually the case by improving the breakdown and dispersal of the chemotherapy’s fatty package at the tumor site.
The investigators repeated experiments using two packaged chemotherapy drugs -- doxorubicin and irinotecan -- and observed similar tumor-killing effects of both when used in combination with the bacteria.
“Packaged” cancer drugs currently are available in microscopic fatty capsules called liposomes which gravitate to tumors because they are too large to fit through the skins of tightly-woven blood vessels surrounding normal tissue and small enough to get through tumor vasculature.
Combining C.novyi-NT and liposomes filled with chemotherapy seems to have its synergistic effect on tumors owing to the presence of an enzyme found lurking in C. novyi-NT cultures, which Ian Cheong, Ph.D., in the Vogelstein lab dubbed liposomase. It destroys fatty membranes and may disrupt the outer layer of liposomes releasing their drug contents.
“Drugs contained in these ‘Trojan horse’ compartments are specifically released at the tumor site by the C-novyi-NT bacteria which may improve the effectiveness and safety of the therapy,” says Cheong who is the lead author of the study.
The scientists note that liposomase could be used in a variety of other targeted therapies besides the bacteria combination. Such approaches could include attaching liposomase to antibodies that have an affinity for specific tumors or adding its DNA code to gene therapy. As many drugs can be packaged within liposomes, the investigators say the approach could have general utility.
In a companion study published in the November 19 online issue of Nature Biotechnology, the Hopkins team decoded the entire C.novyi-NT genome which Zhou says “was instrumental in identifying liposomase and will help improve our bacterial-based therapies.”
Preliminary safety tests of injected C. novyi-NT alone are under way in a small number of cancer patients.
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
Disarray in the brain
18.12.2017 | Universität zu Lübeck
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
16.01.2018 | Materials Sciences
16.01.2018 | Materials Sciences
16.01.2018 | Power and Electrical Engineering